Triptorelin
As of the edition of 20 October 2026, Triptorelin is a protein: marketed, first approved in 1986 (FR); acts on GNRHR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Protein
- Brand name
- Trelstar
- First approved
- 5 March 1986 (FR)
- Approvals on record
- 9 in 5 regions
- Holder of the most recent approval
- Azurity Pharmaceuticals; 5 holders in all
- Registered trials
- 118, 13 stopped early
- Disease areas
- Urinary and reproductive; Cancer; Pregnancy and women's health; Hormones; Skin and connective tissue; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | P30968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 26 | 13 | 2 | 1 |
| Phase 1 | 3 | 1 | 1 | 0 |
| Phase 2 | 21 | 8 | 4 | 6 |
| Phase 3 | 47 | 21 | 16 | 3 |
| Phase 4 | 21 | 9 | 2 | 3 |
| All trials | 118 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ferring Pharmaceuticals | Applicant | 1998 to now |
| Actavis | Later holder | 2010 to now |
| Arbor Pharmaceuticals | Later holder | 2017 to now |
| Verity Pharmaceuticals | Acquired holder | 2020 to now |
| Azurity Pharmaceuticals | Acquired holder | 2022 to now |